Platelet glycogen synthase kinase 3β regulates plasma β amyloid and phosphorylated tau levels in chronic kidney disease patients with cognitive dysfunction; therapeutic role of erythropoietin Post date July 19, 2024 ← The Risk of COVID-19 in Patients of Chronic Kidney Disease with Cognitive Dysfunction Like Alzheimer Disease A Perspective on Erythropoietin as a Potential Adjuvant Therapy → Improving services to trackle the syndemic of HIV and Mental ill Health